United Therapeutics Corporation Proceeds from Sale of Notes Receivable
United Therapeutics Corporation (UTHR) reported Proceeds from Sale of Notes Receivable of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfNotesReceivable · last filed 2025-02-26
- United Therapeutics Corporation proceeds from sale of notes receivable for fiscal 2024 was $0.00.
- United Therapeutics Corporation proceeds from sale of notes receivable for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- United Therapeutics Corporation proceeds from sale of notes receivable for fiscal 2022 was $3.50M.
- United Therapeutics Corporation proceeds from sale of notes receivable for fiscal 2021 was $0.00.
| Period end | Proceeds from Sale of Notes Receivable 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2022-12-31 | $3.50M 10-K · filed 2025-02-26 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-21 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |